John B. Buse, MD, PhD
Verne S. Caviness Distinguished Professor
Chief, Division of Endocrinology
Director, Diabetes Center
Director, NC Translational and Clinical Sciences Institute
Specialty Areas: Prevention and treatment of type 1 diabetes, type 2 diabetes and their complications.
Chronology: MD: Duke University, 1986; PhD: Duke University, 1986; Intern and Resident: University of Chicago, 1986-1988; Endocrinology, Diabetes and Metabolism Fellowship: University of Chicago, 1988-1991; Chief Resident and Instructor: University of Chicago, 1990; Assistant Professor of Medicine: University of Chicago, 1992-1994; Associate Professor of Medicine: University of North Carolina, 1994-2006; Chief: Division of General Medicine and Clinical Epidemiology, University of North Carolina, 2001-2006; Professor of Medicine: University of North Carolina, 2006-present; Chief: Division of Endocrinology, University of North Carolina, 2006-present; Director: Diabetes Center for Excellence, University of North Carolina, 2010-present; Executive Associate Dean for Clinical Research: University of North Carolina, 2011-present; Director: NC Translational and Clinical Sciences Institute, University of North Carolina, 2015-present.
Note: Not accepting new patients at this time.
Dr. Buse’s practice combines clinical care, research and education. He has received international recognition for innovative clinical care and efforts at prevention of type 1 diabetes, type 2 diabetes and their complications. He practices patient-centered care focusing on developing treatment programs in collaboration with patients that meet their needs and expectations. He works with teams of investigators in diabetes clinical trials, comparative effectiveness research and translation of basic science research towards clinical application. Current projects focus in novel treatments including development of glucose-responsive insulin, cardiovascular safety and efficacy of diabetes drugs and developing the evidence-base for treatment guidelines of the future in diabetes care.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB. New England Journal of Medicine 2016 in press.
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. Lingvay I, Manghi FP, García-Hernández P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB. JAMA. 2016; 315:898-907.
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Diabetes Care. 2015; 38:140-9.